Anti-CD20 antibodies

DRUG2 trials

Sponsors

Hansa Biopharma AB, University of Turin, Italy

Conditions

Fibrillary GlomerulonephritisKidney Transplantation in Highly Sensitized Patients

Phase 3

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

CompletedNCT04935177

Hansa Biopharma ABKidney Transplantation in Highly Sensitized Patients

Start: 2021-10-14End: 2025-06-20Updated: 2025-07-16

Phase 4

Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis

CompletedNCT06680349

University of Turin, ItalyFibrillary Glomerulonephritis

Start: 2022-12-01End: 2024-01-02Updated: 2024-11-08

Related Papers

Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization

Transplantation Direct2025-01-093 citations